Skip To Main Content
Katharine Barrientos on Muck Rack

Katharine Barrientos

As seen in: Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Katharine

Contact Katharine, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dendritic cell redundancy enables priming of anti-tumor CD4 + T cells in pancreatic cancer

|
By Courtney T.S. Kureshi, Michael Walsh Verified, Rakeeb Kureshi, Victoire Cardot-Ruffino, Dennis A. Agardy, Lestat R Ali, James M. Dougan, Li Qiang, Jiao Shen, Chong Zuo, Patrick Lenehan, S. Wang, Eugena Chang, Joshua Remland, Lauren K. Brais, Thomas E. Clancy, James Cleary, Jason L. Hornick, Brandon Huffman Verified, Joseph D. Mancias, George Molina, Mark Fairweather, Jonathan A Nowak, Kimberly Perez, Douglas A. Rubinson, Sarah Slater, Ritchell van Dams, Jiping Wang, Brian Wolpin, Lei Zhao, Katharine Barrientos, Ruslan D. Novosiadly, Miranda L. Broz, Harshabad Singh, Michael Dougan, Stephanie K Dougan
| Cell Press Verified
Keywords CD4+ T cells cDC2 IFNγ dendritic cells pancreatic cancer PDAC immune checkpoint blockade PD-1 CTLA-4 STING Introduction Pancreatic ductal adenocarcinoma (PDAC) remains one of the most intractable cancers, with a 13% five-year survival rate.1 PDAC cells produce myeloid cell-recruiting chemokines and growth factors, such as CXCL1 and GM-CSF, which establish a highly immunosuppressive tumor microenvironment2,3 and impact systemic metabolism.4 Although CD8+ T cells exist in most human...
Open in Who Shared Issue with article?
See all 1 articles